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Amyotrophic lateral sclerosis is a fatal neurodegenerative disease characterized by progressive motoneuron loss. Redistribution
of transactive response deoxyribonucleic acid-binding protein 43 from the nucleus to the cytoplasm and the presence of cystatin
C-positive Bunina bodies are considered pathological hallmarks of amyotrophic lateral sclerosis, but their signiﬁcance has not
been fully elucidated. Since all reported rodent transgenic models using wild-type transactive response deoxyribonucleic
acid-binding protein 43 failed to recapitulate these features, we expected a species difference and aimed to make a non-human
primate model of amyotrophic lateral sclerosis. We overexpressed wild-type human transactive response deoxyribonucleic
acid-binding protein 43 in spinal cords of cynomolgus monkeys and rats by injecting adeno-associated virus vector into the
cervical cord, and examined the phenotype using behavioural, electrophysiological, neuropathological and biochemical analyses.
These monkeys developed progressive motor weakness and muscle atrophy with fasciculation in distal hand muscles ﬁrst.
They also showed regional cytoplasmic transactive response deoxyribonucleic acid-binding protein 43 mislocalization with
loss of nuclear transactive response deoxyribonucleic acid-binding protein 43 staining in the lateral nuclear group of spinal
cord innervating distal hand muscles and cystatin C-positive cytoplasmic aggregates, reminiscent of the spinal cord pathology of
patients with amyotrophic lateral sclerosis. Transactive response deoxyribonucleic acid-binding protein 43 mislocalization was
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response deoxyribonucleic acid-binding protein 43 mislocalization leads to a-motoneuron degeneration. Furthermore, truncation
of transactive response deoxyribonucleic acid-binding protein 43 was not a prerequisite for motoneuronal degeneration, and
phosphorylation of transactive response deoxyribonucleic acid-binding protein 43 occurred after degeneration had begun. In
contrast, similarly prepared rat models expressed transactive response deoxyribonucleic acid-binding protein 43 only in the
nucleus of motoneurons. There is thus a species difference in transactive response deoxyribonucleic acid-binding protein 43
pathology, and our monkey model recapitulates amyotrophic lateral sclerosis pathology to a greater extent than rodent models,
providing a valuable tool for studying the pathogenesis of sporadic amyotrophic lateral sclerosis.
Keywords: TDP-43; Bunina bodies; cystatin C; cynomolgus monkeys; amyotrophic lateral sclerosis
Abbreviations: AAV = adeno-associated virus; ALS = amyotrophic lateral sclerosis; FTLD = frontotemporal lobar degeneration;
HEK = human embryonic kidney; TDP-43 = transactive response DNA-binding protein 43
Introduction
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig’s
disease, is an incurable progressive neurodegenerative disease
characterized by muscle weakness and atrophy resulting from
the combined loss of upper and lower motoneurons. Most cases
of ALS are sporadic, and only 10% of ALS cases are of a familial
form. Protein aggregates are one histopathological characteristic of
ALS. A breakthrough in understanding ALS pathogenesis was the
discovery of the 43-kDa transactive response DNA-binding protein
(TDP-43), which was recently identiﬁed as the major component
of the protein aggregates and of the insoluble fraction in the
brains of patients with sporadic ALS and frontotemporal lobar
degeneration (FTLD) (Arai et al., 2006; Neumann et al., 2006).
TDP-43 is now expected to play an essential role in the patho-
genesis of sporadic ALS, possibly equivalent to that of tau and
beta amyloid in Alzheimer’s disease or -synuclein in Parkinson’s
disease.
Human TDP-43 is a highly conserved and ubiquitously ex-
pressed 414 amino acid nuclear protein that binds to both DNA
and RNA (Ou et al., 1995; Buratti et al., 2001). In normal settings,
TDP-43 is a primarily nuclear protein that functions in transcription
regulation, alternative splicing and RNA stabilization (Buratti et al.,
2008), as well as in microRNA metabolism (Buratti et al., 2010).
Pathological TDP-43 can be abnormally truncated, phosphorylated
and ubiquitinated, and most TDP-43 is mislocalized from the
nucleus to the cytoplasm or neurites (Arai et al., 2006;
Neumann et al., 2006). Of note, almost all neurons with cytoplas-
mic TDP-43 accumulations show a dramatic depletion of normal
nuclear TDP-43. Thus, both gain and loss of functions are poten-
tial disease mechanisms, either due to the loss of normal nuclear
TDP-43 expression, or cytoplasmic mislocalization (Arai et al.,
2006; Neumann et al., 2006; Cairns et al., 2007). Therefore, cyto-
plasmic TDP-43 mislocalization with loss of its nuclear staining is a
key feature found in the majority of patients’ brains and spinal
cords (Arai et al., 2006; Neumann et al., 2006).
TDP-43 strictly regulates its messenger RNA levels by directly
binding to an intron in the 30-untranslated region of its own tran-
script and enhancing its splicing (Ayala et al., 2010; Polymenidou
et al., 2011), however, the expression level of TDP-43 can be
upregulated  1.5-fold (Mishra et al., 2007; Gitcho et al., 2009)
in FTLD/ALS. Moreover, mutations in the TDP-43 gene are asso-
ciated with familial ALS (Kabashi et al., 2008; Yokoseki et al.,
2008), in which TDP-43 is also frequently mislocalized within
motoneurons of the spinal cord. These reports support the hypo-
thesis that mislocalization of this protein plays a central role in the
disease pathogenesis. The rodent, Drosophila, Ceanorhabditis ele-
gans and zebraﬁsh models with overexpressed mutant as well as
wild-type TDP-43 show severe motor symptoms and wild-type
TDP-43 localizes exclusively or primarily to nuclei (Ash et al.,
2010; Hanson et al., 2010; Kabashi et al., 2010; Li et al., 2010;
Shan et al., 2010; Voigt et al., 2010; Wils et al., 2010; Xu et al.,
2010; Swarup et al., 2011), although mutant TDP-43 is more
likely to accumulate in the cytoplasm (Swarup et al., 2011). The
results of the rodent models suggested that overexpressed nuclear
wild-type TDP-43 is toxic, but provide little insight for the signiﬁ-
cance of mislocalized wild-type TDP-43. Even in mouse models
that overexpress wild-type TDP-43 with mutated nuclear localiza-
tion signals, total human and mouse nuclear TDP-43 was not
reduced (Igaz et al., 2011) when compared with that in littermate
wild-type controls. Together, these reported mouse models might
have a different TDP-43 pathology from that found in patients
with ALS. Expecting that a primate model of ALS might more
closely reﬂect the TDP-43 pathology in human patients with
ALS, we overexpressed human wild-type TDP-43 in the spinal
motoneurons of a non-human primate, the cynomolgus monkey,
using an adeno-associated virus (AAV) 1 vector.
Materials and methods
Human subjects
Neurologists clinically diagnosed ALS with the aid of electrophysio-
logical examinations. The clinical diagnosis of deﬁnite ALS was based
on El Escorial (Brooks et al., 2000) and electrodiagnostic (De Carvalho
et al., 2008) criteria and conﬁrmed by neuropathological examination
in accordance with published guidelines (Piao et al., 2003).
The patient study protocol was approved by the institutional clinical
study committee at Tokyo Medical and Dental University (No. 799).
Consent forms for autopsy were obtained from legal representatives of
all patients in accordance with the guidelines of the institutional review
boards.
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Ten male adult cynomolgus monkeys (Macaca fascicularis; 3–7 years
old, 3.28–5.10kg) were bred and treated at Tsukuba Primate Research
Centre. The number of monkeys and concentrations of viral stocks
were as follows: one monkey was injected with high-dose Flag-TDP-
43 AAV1 [1   10
13 viral genomes (vg)/ml]; six monkeys were injected
with low-dose Flag-TDP-43 AAV1 (3   10
12vg/ml); three monkeys
were injected with low-dose mock AAV1 (3   10
12vg/ml) as a nega-
tive control. Three monkeys injected with low-dose TDP-43 AAV1
were pathologically examined in the early stage, 3–5 days after the
onset of motor symptoms and the other three monkeys were exam-
ined in the late stage, 4–7 weeks after injection.
Eleven adult male Fisher rats (10 weeks old, Sankyo-lab) were used.
The number of rats and concentrations of viral stocks were as follows:
eight rats were injected with low-dose Flag-TDP-43 AAV1
(3   10
12vg/ml) and three rats were injected with low-dose control
AAV1 (3   10
12vg/ml) as a negative control. Three rats injected
with TDP-43 AAV1 were pathologically examined in the early stage,
1–2 weeks after injection, and the others were examined in the late
stage, 4–9 weeks after injection.
All animal experiments were conducted according to the U.S.
National Institutes of Health Guide for the Care and Use of
Laboratory Animals, and the Guidelines for the Animal Care and
Management of the Tsukuba Primate Research Center and Tokyo
Medical and Dental University.
Constructs
Human wild-type TDP-43 was purchased from Invitrogen. The TDP-43
and Flag-TDP-43 fragments were generated by polymerase chain reac-
tion using the following primer pairs: 50-CCGCTCGAGGCCACCATG
GATTAC AAGGATGACGACGATAAGTCTGAATATATTCGGGTAA
CCGG-30 and 50-CCGCTCGAGCTACATTCCCCAG CCAGAAG
ACTTA-30 for TDP-43, and 50-CCGCTCGAGGCCACCATGGATTACA
AGGATGACGACGAT AAGTCTGAATATATTCGGGTAACCGG-30 and
50-CCGCTCGAGCTACATTCCCCAGCCAGAAGACTTA-30 for
Flag-TDP-43, which contained XhoI digestion sites at the 30- and 50-
ends. The Flag-TDP-43 complementary DNA was subcloned into an
expression cassette ﬂanked with AAV2 inverted terminal repeats
(Stratagene). The cytomegalovirus (CMV) promoter was used to
drive expression.
Adeno-associated virus preparations
Human embryonic kidney (HEK) 293 cells at  70% conﬂuence were
transfected with the AAV1 packaging plasmid pRep2/Cap9 (gift from
Dr James M. Wilson, University of Pennsylvania) and adenovirus
helper plasmid (Stratagene) at a ratio of 1:1:1. At 6h after transfec-
tion, the culture medium was replaced with fresh medium, and the
cells were incubated for 48h. The cells were then harvested from the
culture dishes and pelleted by centrifugation, resuspended in
phosphate-buffered saline and subjected to three rounds of freeze–
thawing. Cell debris was then pelleted by centrifugation at 1200g
for 15min. AAV vectors were puriﬁed using ammonium sulphate pre-
cipitation and iodixanol (Axis-Shield) continuous gradient
centrifugation.
Size-exclusion chromatography was performed using an AKTA
Explorer 100 HPLC system (GE Healthcare) equipped with a 2-ml
sample loop. A Superdex 200 10/300 GL column (GE Healthcare)
was equilibrated with MHA buffer (3.3mM MES, 3.3mM HEPES,
3.3mM NaOAc, 50mM NaCl, pH 6.5). The vector-containing
fractions were loaded onto the column at a ﬂow rate of 0.5ml/min,
and the eluate was collected as 0.5ml fractions over the duration of
one column volume (23ml). AAV peak fractions were identiﬁed by
280/260nm absorbance and real-time quantitative polymerase chain
reaction using vector-speciﬁc primers. The puriﬁed AAVs were then
concentrated further by using Amico Ultra-4 tubes (Ultracel-30k,
Millipore) to a ﬁnal concentration of 1   10
13 genome copies/ml, as
determined by real-time quantitative polymerase chain reaction.
The genome copy number was calculated by TaqMan PCR
(Applied Biosystems). The vectors were treated with Benzonase and
digested with proteinase K (Wako Pure Chemical Industries) for 1h
and puriﬁed by phenol–chloroform extraction. The TaqMan primers
and probe were designed as follows: forward primer: 50-CAGGCTGGT
CCAACTCCTA-30, reverse primer: 50-GCAGTGGTTCACGCCTGTAA-
30, and probe: 50-TACCCACCTTGGCCTC-30. The designed TaqMan
PCR fragment was located in the human growth hormone polyadeny-
lation site in the vector.
Successful viral assembly of control AAV and transgene expression
were conﬁrmed by immunoblot analysis using HEK 293 cells infected
with AAV (Supplementary Fig. 1), as described below.
HEK-293 cells were cultured in Dulbecco’s modiﬁed Eagle’s medium
containing 10% foetal bovine serum with 1% penicillin/streptomycin.
The cells in 12-well plates were infected by Flag-TDP-43 AAV1
(5   10
10vg/ml). At 48h after infection, cells were harvested by
gentle scraping in lysis buffer [20mM Tris–HCl, 150mM NaCl, 1%
NP-40, 0.1% deoxicolate, 1% sodium dodecyl sulphate, 1mM
EDTA, 1mM EGTA, 10mM b-glycerophosphate, 5mM NaF and
Complete protease inhibitor cocktail (Roche Diagnostics)]. Equal
amounts of total cellular protein were mixed with 5  Laemmli
sample buffer, denatured at 95 C for 5min, and separated with
10% sodium dodecyl sulphate polyacrylamide gel electrophoresis.
The proteins were transferred to PVDF membranes. After blocking
with 3% gelatin (Wako Pure Chemical Industry) in Tris-buffered
saline or 5% skimmed milk (Wako Pure Chemical Industry) in
Tris-buffered saline-Triton X-100, the membranes were incubated
overnight with the following primary antibodies: anti-M2 (1:2000);
anti-pan-TDP-43 (1:2000); and anti-VP1, VP2 and VP3 of AAV
(1:1000). After incubation with an appropriate horseradish peroxi-
dase-conjugated secondary antibody (Santa Cruz Biotechnology),
labelling was detected with the ECL Plus
TM Chemiluminescent
Detection System (GE Healthcare) or SuperSignal (Thermo Scientiﬁc).
Stereotaxic injection of
adeno-associated viral vectors
All surgical operations were performed under general anaesthesia.
Ketamine hydrochloride (Ketalar, Sankyo) was intramuscularly admin-
istered at a dose of 5mg/kg as a pre-anaesthetic agent, and general
anaesthesia was maintained with isoﬂurane (Forane, Abbott) and
oxygen after tracheal intubation. The monkeys were positioned in a
stereotaxic frame. After a bilateral laminectomy and opening the dura
in the midline at C5–6, AAV vectors were stereotaxically injected into
the side ipsilateral to the dominant hand. The injection site was deter-
mined and depth of needle insertion was calculated from the pre-
operatively taken MRI of cervical spinal cord. AAV stock (5ml) was
injected through a 31-gauge needle connected to a 10-ml Hamilton
microsyringe in 2min. The needle remained in place for 10min and
was removed slowly. The dura and skin were sutured and monkeys
returned to their individual cages. The monkeys received 0.5mg/kg
butorphanol tartrate (Stadol, Bristol-Myers Squibb) intramuscularly for
3 days to alleviate any postoperative pain.
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cocktail of 1.5ml chloral hydrate (70mg/ml, Wako Pure Chemical
Industry) and 0.1ml ketamine hydrochloride (70mg/ml) at a dose of
6ml/kg. A left side hemi-laminectomy was performed from C4 to C6.
On the left side of the C6 segment, 1.5ml of viral stock was manually
injected through sharpened microcapillary glass (PN-30 puller,
Narishige) connected via silicone to a 10-ml Hamilton microsyringe at
a rate of 0.5ml/min. The sharpened microcapillary glass remained in
place for 3min and was removed slowly. The skin was sutured, the
rats placed on a heating pad until they began to recover from surgery,
and then returned to their individual cages.
For detection of the AAV genome in the spinal cord, total DNA
was extracted from spinal cord with homogenized buffer containing
0.5% sodium dodecyl sulphate, 10mM Tris–HCl pH 8.0, and 10mM
EDTA pH 8.0, and polymerase chain reactions were carried out with
the following primer pair: 50-CGCTGTTTTGACCTCCATAGAA-30 and
50-AGGCGGTACTTACGTCACTCTTG-30 for the cytomegalovirus
b-globin intron.
Behavioural analysis
For monkeys, to evaluate weakness of the forelimb muscles on the
AAV-injected side (the dominant-hand side), we performed the ‘apple
test’. The front fence of the cage was altered to have two holes and
trays on the right and left side. A piece of apple was placed in line
from back (monkey side) to front (observer side) on the left or right
tray at 3, 6, 9 and 12cm from the front fence during a session.
The monkeys were trained to reach a small piece of apple on the
trays through the hole. Four sessions were performed alternately for
each side. We analysed how frequently a monkey used his dominant
hand to pick up apples before and every week after the operations.
We also carefully observed behaviour of the monkeys in daily life
every day and recorded video monitoring for 30min per week.
For rats, to evaluate weakness of the forelimb muscles, we mea-
sured grip strength using a special device (Muromachi Kiki) as previ-
ously described (Anderson, 2005).
Electrophysiological assessment
The nerve conduction study and needle EMG studies were performed
under anaesthesia with a combination of 7mg/kg ketamine hydro-
chloride and 1.2mg/kg xylazine administrated intramuscularly. Nerve
conduction studies were performed in the bilateral median nerves
using conventional procedures and an EMG Machine (MEB-2300,
Nihon-koden). The recording surface electrode was placed over the
belly of the thenar eminence with a reference electrode at the meta-
carpophalangeal joint of the thumb, and compound muscle action
potentials were elicited after the stimulation of the median nerve at
the wrist. The peak-to-peak amplitudes were measured for all com-
pound muscle action potentials. Nerve conduction studies were exam-
ined before AAV injection and every 1 or 2 weeks after. The needle
EMG study was performed in the ﬁrst dorsal interosseous, ﬂexor carpi
ulnaris and biceps brachii muscles using a conventional concentric
needle electrode used in human studies (TECA Elite, CareFusion),
4–6 weeks after AAV injection.
Neuropathological examinations
Animals were deeply anaesthetized ﬁrst with intramuscularly adminis-
tered 7mg/kg ketamine hydrochloride and then with intravenously
administered 25mg/kg pentobarbital. After conﬁrming the absence
of a blink reﬂex, the spinal cord and skeletal muscles were removed.
For neuropathological examination, human and animal spinal cord sam-
ples were immersion ﬁxed in 10% neutral buffered formalin, processed
conventionally, embedded in parafﬁn, cut into 4-mm-thick sections and
stained with haematoxylin and eosin. For immunostaining, sections were
deparafﬁnized, pretreated in 0.5% periodic acid, autoclaved for 5min at
121 C and then incubated free-ﬂoating overnight at 4 C with the fol-
lowing primary antibodies: M2 (1:500), anti-pan-TDP-43 (1:1000),
anti-pS409/410-TDP-43 (1:500), anti-ubiquitin (1:500), anti-p62
(1:500), anti-cystatin-C (1:1000), anti-GFAP (1:500), anti-GLUT-5
(1:500) and SMI31 (1:200). Following brief washes, the sections were
sequentially incubated with polymer immunocomplex (Dako)
Immunoreactive elements were visualized by treating sections with
3,30 diaminobenzidine tetroxide (DAB-4HCl, Dojin Kagaku) with or
without nickel ammonium chloride. The sections were then counter-
stained with haematoxylin. For double-immunostaining, the deparafﬁ-
nized sections were stained with Sudan Black B to avoid
autoﬂuorescence. The free-ﬂoating sections were incubated overnight
at 4 C in solutions containing the primary antibodies. The sections
were then incubated with AlexaFluor 488- or 555-conjugated second-
ary antibodies (1:500, Invitrogen), and DAPI nuclear stain (1:500,
Santa Cruz Biotechnology) for 1h. All sections were examined using
a confocal microscope (NIKON or Carl Zeiss).
Animal anterior root samples were ﬁxed with a mixture of 2.5%
glutaraldehyde in 0.1M phosphate buffer (pH 7.4) at 4 C overnight,
and then further ﬁxed in 1% osmium tetroxide in 0.1M phosphate
buffer (pH 7.4) for 1h. The well-ﬁxed tissues were dehydrated in
graded ethanol and embedded in Epon 812 (Poly/Bed 812,
Polyscience). The ﬁxed roots were transversely cut into 1-mm-thick
sections and stained with toluidine blue.
For counting of anterior horn neurons in the spinal cord, monkey
eighth cervical segments were serially cut at 4-mm thickness, and every
ﬁfth section was stained with haematoxylin and eosin. The previous
and next serial sections (that is, every fourth and sixth sections) were
immunostained with anti-pan-TDP-43 or anti-Flag antibodies. The
number and minimum diameters of neurons with nuclei in the lateral
or medial nuclear groups in 15 sections were evaluated using the
Image J software program from the U.S. National Institutes of Health.
Antibody information
Weusedthefollowingprimaryantibodiesforimmunostainingandimmu-
noblot analyses: mouse monoclonal anti-Flag (M2, Sigma); rabbit poly-
clonal anti-pan-TDP-43 (10782-1-AP, ProteinTech Group); rabbit
polyclonal anti-C-terminal TDP-43 (12892-1-AP, ProteinTech Group);
rabbit polyclonal anti-phosphorylated S409/410 TDP-43 (Cosmo Bio);
rabbit polyclonal anti-ubiquitin (Dako); rabbit polyclonal anti-cystatin-C
(Dako); mouse monoclonal anti-phosphorylated neuroﬁlament (SMI31,
Sternberger Monoclonals);rabbit polyclonal anti-glial ﬁbrillary acidic pro-
tein (GFAP) (Dako); rabbit polyclonal anti-glucose transporter 5
(GLUT-5, IBL); rabbit polyclonal and mouse monoclonal anti-peripeherin
(AB1530andAB1527,Chemicon);mousemonoclonalanti-neuroﬁlament
light (N5139, Sigma) antibody; anti-p62 (GP62-C, Progen);
anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH, Biodesign),
and anti-AAV capsid proteinsVP1, VP2 and VP3 (ProgenBiotechnik).
Sequential biochemical fractionation,
dephosphorylation and immunoblot
analysis
Frozen frontal cortex or spinal cord (50–250mg) was homogenized in
10 volumes of buffer A (10mM Tris–HCl pH 7.5, containing 1mM
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X-100 at a ﬁnal concentration of 1%, the homogenate was incubated
for 30min at 37 C and spun at 100000g for 20min at 20 C.
The pellet was homogenized in 20 volumes of buffer A containing
1% sarkosyl, incubated for 30min at 37 C and spun at 100000g
for 20min at 20 C. The sarkosyl-insoluble pellet was homogenized
in four volumes of buffer A containing 1% CHAPS [3-
[(3-cholamidopropyl)dimethylammonio]-1-propanesulphonate] and
spun at 100000g for 20min. The pellet was sonicated in 0.5 volume
of 8mol/l urea buffer, cleared by centrifugation at 100000g for
20min at 20 C, and used for immunoblotting. The samples before
( ) and after (+) treatment with lambda protein phosphatase
(1600U/ml, New England Biolabs) were subjected to 10% sodium
dodecyl sulphate polyacrylamide gel electrophoresis. Proteins in the
gel were then transferred onto a polyvinylidene diﬂuoride (PVDF)
membrane (Millipore). After blocking with 3% gelatin (Wako Pure
Chemical Industries) in Tris-buffered saline (50mM Tris–HCl pH 7.5,
150mM NaCl), the membranes were incubated overnight with the
following primary antibodies: anti-M2 (1:2000); anti-C-TDP-43
(1:1200); anti-phosphorylated S409/410 TDP-43 (1:2000); anti-p62
(1:3000) and anti-GAPDH (1:2000). After incubation with an appro-
priate horseradish peroxidase-conjugated secondary antibody (Santa
Cruz Biotechnology), labelling was detected by a 3,30diaminobendi-
zene reaction intensiﬁed with nickel chloride (Metal-Enhanced DAB
Substrate Kit, Thermo Scientiﬁc), the ECL Plus
TM Chemiluminescent
Detection System (GE Healthcare), or SuperSignal (Thermo Scientiﬁc).
Quantitative real-time polymerase
chain reaction assay
Total RNA was extracted from whole-brain homogenates with Isogen
(Nippon Gene). DNase-treated RNA (2.5mg) was reverse-transcribed
with SuperScript III and random hexamers (Life Technologies).
Complementary DNA was ampliﬁed by the quantitative TaqMan
system by using the Light Cycler 480 Real-Time PCR Instrument
(Roche Diagnostics). The primers and probes speciﬁc for Flag-tagged
human TDP-43, rat TDP-43 (NM_001011979.2) and monkey TDP-43
(XM_001102660.2) were designed. Relative Flag-human TDP-43 mes-
senger RNA levels were calculated in comparison to endogenous rat or
cynomolgus messenger RNA levels. A list of all primers and probes
used in this study is provided in Supplementary Table 1.
Statistical analysis
The data obtained from independent experiments are presented as
means   SEM.
Statistical analysis of spinal neuron counts and axonal density among
TDP-43-expressed monkey group in early, late stage and control
monkey group by one-way ANOVA with Bonferroni’s post hoc test.
P50.05 was considered signiﬁcant.
Results
Overexpressing wild-type TDP-43 in the
monkey cervical cord leads to progres-
sive motor weakness and muscle atro-
phy with fasciculation
AAV expressing Flag-tagged TDP-43 (Supplementary Fig. 2) was
directly injected into the sixth cervical segment on the
dominant-hand side of seven monkeys. All monkeys developed
progressive motor weakness and muscle atrophy with marked fas-
ciculation in the forelimb on the injected side (Fig. 1A and B,
Supplementary Video 1). Two to 3 weeks after the injection, the
TDP-43-expressing monkeys ﬁrst showed some difﬁculty in taking
time to pick up pieces of apple using the dominant hand on the
injected side in the apple test, and changed to use the
non-dominant hand (Fig. 1C). On observation by video monitor-
ing, they could reach and grasp the ceiling fence at the onset of
clumsiness of picking apples, but 1–3 weeks later could not ﬂex
the elbow joint and raise the forelimb, indicating the motor weak-
ness had spread to the proximal muscles (Fig. 1D). In the late
stage, 2–5 weeks after the onset, the dominant hand muscles
became completely paralysed (Fig. 1A), and muscle weakness
and atrophy had spread to the contralateral, un-injected side
limb muscles (Fig. 1B and E). One of TDP-43-expressing monkeys
showed respiratory failure at the end stage. The control monkeys
did not show obvious motor symptoms, indicating surgical proced-
ure or virus toxicity was minimal (Fig. 1C–E and Supplementary
Video 2).
Electrophysiological ﬁndings
Electrophysiologically, in all TDP-43-expressing monkeys, the
compound muscle action potential of the thenar muscle evoked
by stimulation of the median nerve at the wrist progressively
decreased in size with preservation of conduction velocity, and
the muscle became unexcitable in the late stage (Fig. 2A). In
contrast, three monkeys injected with control AAV did not
show a marked change compound muscle action potential size
(Fig. 2A). In TDP-43-expressing monkeys, the compound muscle
action potential size on the contralateral side was not changed
in the early stage (3–5 days after the onset of motor symptoms),
but showed milder reduction of compound muscle action poten-
tial size in the late stage (Fig. 2B). Needle EMG revealed ro-
bust fasciculation potentials, and denervating potentials of
positive sharp waves and ﬁbrillation potentials in the late stage
(Fig. 2C).
Cytoplasmic mislocalization with loss
of endogenous monkey TDP-43,
dystrophic neurites and cystatin
C-positive granules in the cytoplasm
Neuropathologically, an anti-Flag antibody widely detected exo-
genous TDP-43 in neurons from the second cervical to the second
thoracic segments on both sides, and was observed in almost all
neurons on the injected side from the fourth to eighth cervical
segments. Generally, Flag immunoreactivity was not detected in
the glial cells. There was no inﬂammatory reaction except for in
the area around the injection site. In the late stage, exogenous
TDP-43 was observed in either the nucleus or cytoplasm (Fig. 3A).
Pan-TDP-43 staining revealed that most motoneurons with
cytoplasmic TDP-43 lost endogenous monkey TDP-43 staining
(Fig. 3B), which normally localized in the nucleus (Fig. 3C).
Mislocalized TDP-43 was diffusely distributed in the cytoplasm
Non-human primate model of ALS Brain 2012: 135; 833–846 | 837and, in some neurons, granularly aggregated (Fig. 3B). Proximal
and distal dystrophic neurites were occasionally observed (Fig. 3A
and B). Phosphorylation of TDP-43 in the nucleus or cytoplasm
was not clear in the early stage, but became obvious in the late
stage (Fig. 3D). Anti-ubiquitin and anti-p62 antibodies did not
show a clear abnormal signal. Astrogliosis and microgliosis were
observed (Supplementary Fig. 3). A small fraction of the moto-
neurons expressing TDP-43 in the nucleus characteristically dis-
played coarse cystatin C-positive granules in the cytoplasm
(Fig. 3E) in the neurons with exogenously expressed TDP-43 in
the nucleus. There were no neurons with co-localized cystatin
C-positive granules and TDP-43 aggregates in the cytoplasm.
We also observed aberrant accumulation of phosphorylated neu-
roﬁlaments (Fig. 3F) and peripherin (Supplementary Fig. 4) in the
cytoplasm of spinal motoneurons, a common pathological feature
in patients with ALS (Munoz et al., 1988; Corbo and Hays, 1992).
Immunostaining with an anti-Flag antibody identiﬁed its nuclear or
cytoplasmic immunoreactivity in some Betz cells in the precentral
gyrus restricted to the forelimb area contralateral to the injection.
This Flag immunoreactivity was not observed in other cortical
areas (including hippocampus and frontal lobe, which are prefer-
entially affected in patients with FTLD), thalamus, basal ganglia
and white matter, or in glial cells (Supplementary Fig. 5).
Characteristic regional mislocalization
of TDP-43 in motoneurons of the
anterior horn similar to amyotrophic
lateral sclerosis spinal cords
In the early stage, 3–5 days after the onset of hand clumsiness,
TDP-43 mislocalization of diffuse staining pattern was observed in
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Figure 1 Overexpressing wild-type TDP-43 in the monkey cervical cord leads to progressive motor weakness and muscle atrophy.
(A) Motor paresis of the forelimb on the injected side (encircled) in TDP-43 AAV-injected monkeys. (B) Constructed (top) and axial
(bottom) MRI images of upper arm muscles before (pre) and 4 weeks after (post) injection, indicating a marked muscle atrophy of upper
and forearms as well as hand muscles, predominantly on the injected side (left side). (C) Apple test. Frequency with which the dominant
hand was used to pick up apples. (D and E) Behavioural analysis assessing muscle strength of forearms on the injected side (D) and
contralateral side (E). A score of 3 indicates that the monkeys can hang on the ceiling fence; score of 2, they can grasp but not hang on the
ceiling fence; score of 1, they can raise the forelimb but not reach ceiling fence; score of 0, they cannot raise the forelimb. Measurements
that appear to end before the end of the experiment are from the three monkeys that were pathologically examined in the early stage.
838 | Brain 2012: 135; 833–846 A. Uchida et al.most motoneurons in the lateral nuclear group of the anterior
horn. In contrast, almost all neurons in other areas of the spinal
cord including the posterior horn showed ﬂag signal of exogen-
ously expressed TDP-43 only in the nucleus (Fig. 4A and D).
Importantly, the contralateral lateral nuclear group also exhibited
TDP-43 mislocalization on the side of forelimb that did not yet
show obvious motor symptoms (Supplementary Fig. 6). Signals of
exogenous Flag-TDP-43 were detected by real-time polymerase
chain reaction on the contralateral half of the spinal cord
(Supplementary Fig. 7). However, this distribution indicates
that this regional selectivity is not due to differences in the con-
centration of the injected AAV, but rather is due to properties of
the affected neurons. In the late stage, 2–5 weeks after onset, the
percentage of motoneurons with TDP-43 mislocalization
decreased  47% in the lateral nuclear group, and was 52% in
the ventromedial nuclear group (Figs 3B and 4D). The number
of large motoneurons (520mm) in the early stage in this
lateral nuclear group did not change, but in the late
stage, was reduced by  42% (Fig. 4B, C and E). In contrast,
the reduction in the number of large neurons in the ventromedial
nuclear group was not signiﬁcant (control, 1.78   0.20 versus
TDP-43, 1.68   0.18/section, P = 0.80). Astrogliosis was also
more prominent in the lateral area than in the ventromedial
area of the anterior horn (data not shown). Motoneuronal degen-
eration of the lateral nuclear group was also conﬁrmed by study-
ing the anterior roots of the eighth cervical segment, which
showed frequent myelin ovoids and loss of large myelinated
axons (58mm) in the late stage, although they were almost
normal in the early stage (Fig. 5A–C). This axonal loss in the an-
terior roots is consistent with pathological change of the the-
nar muscle, showing numerous small angulated atrophic ﬁbres
(Fig. 5D).
We furthermore examined whether such a regional change of
TDP-43 mislocalization occurs in spinal cord of nine patients with
ALS with upper limb weakness and hand muscle atrophy. TDP-43
mislocalization was observed much more in the lateral nuclear
group than in the ventromedial nuclear group of the cord at the
eighth cervical segment (Fig. 6A–C).
Figure 2 Electrophysiological ﬁndings for motor symptoms of the monkeys. (A) Compound muscle action potentials (CMAPs) in the
thenar muscle after stimulation of the median nerve at the wrist. They gradually decreased in size, and became inexcitable in the late stage.
There was no change of compound muscle action potential size in the control monkey. (B) Ratio of the compound muscle action
potential size 3–5 days after the onset (early stage) or 2–5 weeks after the onset (late stage) to the size before injection. In the early stage,
there was no reduction in compound muscle action potential size on the contralateral side, but moderately attenuated in the late stage.
(C) Needle EMG ﬁndings of the forearm muscle. Circles indicate fasciculation potentials; open triangles, positive sharp waves; ﬁlled
triangles, ﬁbrillation potentials.
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pathology in rodents and primates
To investigate interspecies differences in TDP-43 pathology, we
injected the identical TDP-43-expressing AAV at the same concen-
tration into rat cervical cords. Expression level of Flag-TDP-43
messenger RNA around the injection site in rat spinal cord was
420-fold higher than that of endogenous TDP-43 level, and this
fold change was similar to that in monkey spinal cord (Fig. 7A).
Rats injected with TDP-43 AAV showed progressive motor weak-
ness (Fig. 7B), measured by grip strength. Importantly, exogenous
TDP-43 was observed only in the nuclei of motoneurons in both
early (14 days after injection of AAV) and late (4 weeks after
injection of AAV) stages (Fig. 7C). Since mislocalization of
TDP-43 in the monkey spinal cords was more prominent in the
early stage (14 days), we also examined the pathology of rat
spinal cords at a very early stage (7 days); however, the weak
Flag immunoreactivity was still limited to the nucleus of moto-
neurons (data not shown). Furthermore, this rat model failed to
exhibit cystatin C-positive aggregates, dystrophic neurites, or ab-
errant accumulation of phosphorylated neuroﬁlaments in the cyto-
plasm of spinal motoneurons (Fig. 7D). These neuropathological
ﬁndings indicate that this rat model was less similar to human ALS
than our monkey model in TDP-43 localization and other charac-
teristic features of ALS.
Detection of the 25-kDa C-terminal
fragment and phosphorylated TDP-43
in the early stage
Biochemically, immunoblot analysis of monkey spinal cord demon-
strated that the exogenous Flag-tagged TDP-43 became much
more insoluble than endogenous TDP-43 (Fig. 8A). The phosphor-
ylation of TDP-43 was unclear in the early stage (Fig. 8B) but
clearly detected later (Fig. 8C). Neither a C-terminal nor a phos-
phospeciﬁc TDP-43 antibody detected the 25-kDa C-terminal
fragment (Fig. 8A–C). These suggest that neither phosphorylation
of TDP-43 or its 25-kDa C-terminal fragment in spinal cord is
necessary to initiate motoneuronal dysfunction and degeneration
in our monkeys.
Discussion
Frequent mislocalization of TDP-43 in the cytoplasm and loss of its
nuclear staining are major pathological hallmarks in the histological
Figure 3 Neuropathological ﬁndings of monkey spinal cords of TDP-43–overexpressed monkeys at the late stage (A, D–F), and control
with mock AAV (C). (A–D) TDP-43-overexpressed spinal cord immunostaining using antibodies to Flag (A), pan-TDP-43 (B) and pS409/
410 TDP-43 (D) demonstrated mislocalization in cytoplasm (arrows), and dystrophic neurites (asterisks) as well as normal localization in
nuclei (arrowheads), whereas normal spinal cord showed only nuclear localization of TDP-43. (E) Co-labelling of a motoneuron expressing
TDP-43 in the nucleus with antibodies to cystatin C (red) and Flag (green). The nucleus is labelled with DAPI. (F) Immunostaining using
SMI31 revealed the aberrant presence of phosphorylated neuroﬁlament in the neuronal cytoplasm (arrows). Scale bars: 20mm.
Immunostainings of spinal cord with control mock AAV using the antibodies to Flag, pS409/410 TDP-43, cystatin C and SMI31 are shown
in Supplementary Fig. 7.
840 | Brain 2012: 135; 833–846 A. Uchida et al.diagnosis of ALS and FTLD (Geser et al., 2010). The classiﬁcation
of TDP-43 proteinopathy is based on a combination of neuronal
cytoplasmic inclusions and dystrophic neurites (Mackenzie et al.,
2011). The morphological features in our monkeys are close to
type B TDP-43 proteinopathy, which is usually observed in the
brains of patients with ALS. The only difference between the path-
ology of our monkeys and type B TDP-43 proteinopathy is that
mislocalized cytoplasmic TDP-43 was usually diffuse and neuronal
cytoplasmic inclusions were less frequent in our monkeys. Since
this monkey is an acute model for TDP-43 pathology, it possibly
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Figure 4 Regional mislocalization of TDP-43 and cell death in monkey spinal cords. (A) Sections from the injected side of the eighth
cervical segment of the cord taken at the early stage and immunostained with an anti-Flag antibody. Most neurons in the lateral nuclear
group (area encircled by broken line) showed cytoplasmic mislocalization of TDP-43 (inset), but almost all neurons in other areas expressed
exogenous TDP-43 in the nucleus. Scale bars: 200mm. (B and C) The eighth cervical level of cord from monkeys injected with TDP-43–
expressing (B) and control (C) AAV, taken at the late stage and stained with haematoxylin and eosin. The number of large motoneurons
decreased in the lateral nuclear group (areas encircled by broken line), but not in ventromedial nuclear group (areas encircled by red solid
line). Scale bars: 200mm. (D) Percentage of neurons with nuclear (black) or cytoplasmic (red) localization of exogenous TDP-43 in the
lateral nuclear groups on the injected side. Neurodegeneration affects the lateral nuclear group more than the ventromedial nuclear group.
(E) Cell count of neurons in the lateral nuclear group on haematoxylin and eosin staining. Mean   SEM. n =3 ,* P50.05. Lat = lateral
nuclear group; Med = ventromedial nuclear group.
Non-human primate model of ALS Brain 2012: 135; 833–846 | 841takes more time for diffusely mislocalized TDP-43 to be aggre-
gated. Moreover, in the spinal cords of patients with ALS, diffuse
cytoplasmic TDP-43 staining is more common, and neuronal cyto-
plasmic inclusions are less frequent than in the brain and may even
be absent (Giordana et al., 2010). Thus, our monkey model shows
the key features of TDP-43 proteinopathy as seen in the ALS
spinal cord.
Interestingly, despite the diffuse expression of exogenous
TDP-43 in the spinal cord, TDP-43 mislocalization and neuron
loss predominantly occurred in the lateral nuclear group in
Rexed lamina IX, in which large neurons are mostly -moto-
neurons (Carpenter et al., 1983). The sensory neurons and inter-
neurons in laminae III–VIII rarely showed TDP-43 mislocalization,
and large motoneurons in the ventromedial nuclear group, most of
which are also -motoneurons, showed much less TDP-43 mislo-
calization and neuron loss. Within lamina IX, the lateral nuclear
group innervates the distal, fast-contracting muscles of the extre-
mities, and the ventromedial nuclear group innervates the
posture-related, continuously contracting muscles attached to the
axial skeleton (Carpenter et al., 1983). This regional vulnerability
among -motoneurons is consistent with the distal hand or foot
muscles being the ﬁrst involved in 73% of patients with
non-bulbar ALS (Harverkamp et al., 1995; Ko ¨rner et al., 2011)
and might be related to axon length, which affects axonal trans-
port (Bilsland et al., 2010), or to the preferential susceptibility of
fast-fatigue rather than slow motoneurons (Dengler et al., 1990;
Pun et al., 2006). Furthermore, in nine patients with ALS, more
TDP-43 mislocalization was observed in the lateral nuclear group
than in the ventromedial nuclear group of the eighth cervical cord
segments. Taking these results together, we think that the tropism
of TDP-43 mislocalization was similar to that of ALS pathology.
However, expression levels of exogenous wild-type TDP-43 in our
monkey and rat models were very high ( 20-fold higher than
that of endogenous TDP-43), which was partly due to lack of
30-untranslated region in our TDP-43 expression construct. This
is probably because TDP-43 controls its own expression through
a negative feedback loop by binding to 30-untranslated region
sequences in its own messenger RNA (Ayala et al., 2010;
Polymenidou et al., 2010). The unphysiologically high level of
TDP-43 expression in our animal models should be taken into
consideration when interpreting our ﬁndings.
Since Flag TDP-43 messenger RNA was detected in the spinal
cord contralateral to the injected side by real-time polymerase
chain reaction analysis, the AAV virus was shown to spread con-
tralaterally through the spinal cord causing motor paresis and re-
duction of compound muscle action potential size in the opposite
forelimb. However, it is still possible that there was concomitant
cell-to-cell or trans-synaptic propagation of Flag TDP-43 protein in
the spinal cord. Moreover, it is interesting that the Flag-TDP-43
signal was selectively extended into Betz cells in the forelimb area
of precentral gyrus contralateral to the injection side, which can be
explained by a retrograde progression from -motoneuron in the
cervical cord. More sophisticated experimental paradigms are ne-
cessary to distinguish whether it is the AAV vector itself,
Figure 5 Pathological ﬁnding of monkey anterior root and skeletal muscle. Toluidine blue staining of the eighth cervical anterior roots on
the injected side in the early (A) and late (B) stages, and their myelinated axon densities (C). Mean   SEM, n =3 ,* * P50.01. (D)
Transverse section of the biceps brachii muscle from a TDP-43–expressing monkey 4 weeks after injection, stained with ATPase (pH 10.6).
Small angulated atrophic changes of type I (arrowheads) and type II (arrows) ﬁbres, with predominant involvement of type II ﬁbres, can be
seen. Scale bar: 50mm.
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ecule responsible for this progression, which is a prime objective
for our future study.
Bunina bodies are small, cystatin C-positive, eosinophilic cyto-
plasmic inclusions and are generally considered a speciﬁc hallmark
of sporadic ALS (Okamoto et al., 1993; Mitsumoto et al., 1998).
Importantly, Bunina bodies are absent in familial ALS that is due to
the SOD1 mutation (Tan et al., 2007) or FUS/TLS mutation
(Tateishi et al., 2010), but they have been detected in familial
ALS with the TDP-43 mutation (Yokoseki et al., 2008) as well
as in sporadic ALS. These imply an association between Bunina
bodies and TDP-43 pathology in sporadic ALS. From this point
of view, the generation of cystatin C-positive cytoplasmic aggre-
gates in our monkeys might strengthen their pathological value as
a model of sporadic ALS.
Biochemically, TDP-43 proteinopathy is characterized by
decreased solubility, phosphorylation and the generation of
25-kDa C-terminal fragment (Arai et al., 2006; Neumann et al.,
2006; Hasegawa et al., 2008). In TDP-43-overexpressing mon-
keys, the exogenous TDP-43 became much more insoluble than
endogenous TDP-43 of control monkeys, indicating that expres-
sion of large amounts of exogenous wild-type TDP-43 can render
it insoluble. Unexpectedly, the solubility of endogenous monkey
TDP-43 did not become insoluble in TDP-43-overexpressing mon-
keys. The expectation would be that exogenous insoluble TDP-43
would recruit endogenous monkey TDP-43 and alter its solubility.
In this biochemical aspect of TDP-43 solubility, our monkey model
differs from patients with ALS.
The pathological role of phosphorylated TDP-43 is still unclear;
TDP-43 phosphorylation in culture cells enhances its oligomeriza-
tion (Hasegawa et al., 2008), but experiments with a
phosphorylation-resistant mutant TDP-43 indicated that phosphor-
ylation is not required for inclusion formation or cellular toxicity
(Zhang et al., 2009). In our monkeys, phosphorylation of TDP-43
was a late event but not observed at 4 days after symptom onset.
This ﬁnding suggests that TDP-43 phosphorylation is not
Figure 6 Pan-TDP-43 staining of spinal cords of patients with ALS. (A) Autopsied eighth cervical segment of spinal cord immunostained
with pan-TDP-43 antibody. Scale bars: 200mmi nA and 50mm in window insets. (B) Schematic illustration of the distribution of neurons
with TDP-43 mislocalization, made by summing data from ﬁve sections (at 20-mm intervals). (C) Percentage of neurons with nuclear or
cytoplasmic localization of exogenous TDP-43 in the lateral and medial nuclear groups. More frequent TDP-43 mislocalization in the lateral
nuclear group in spinal cords of patients with ALS than in the medial nuclear group. Mean   SEM, n = 10, P50.01. Scale bars: 50mm.
Lat = lateral nuclear group; Med = ventromedial nuclear group.
Non-human primate model of ALS Brain 2012: 135; 833–846 | 843Figure 8 Biochemical analysis of monkey spinal cords. (A) Immunoblot of cervical spinal cord lysates from TDP-43–expressing monkeys
(4 weeks after injection) and patients with ALS using antibodies recognizing the C-terminus of TDP-43 and Flag. SC = spinal cord of
patient with ALS; 1 = TDP-43–expressing HEK 293T cell lysate; 2 = Flag-TDP-43–expressing HEK 293T cell lysate; T = 1% Triton
X-100-soluble; S = 1% sarkosyl-soluble; U = 8mol/l urea-soluble fraction; fTDP = Flag-TDP-43. A longer exposure (second panel from
top) revealed the 25-kDa C-terminal fragment in the spinal cord of a patient with ALS (arrow). The  30-kDa band noted in the
Triton-soluble fraction from the spinal cord of a TDP-43–expressing monkey (asterisk) was different from the 25-kDa C-terminal fragment
(arrow). (B and C) Immunoblot of 8mol/l urea-soluble fraction from the monkey spinal cord harvested 4 days (B) and 2 weeks (C) after
onset of symptoms, using antibodies to pS409/410 TDP-43 (top) and C-TDP-43 (bottom) before ( ) and after (+) treatment with
lambda protein phosphatase (PPase). 3 = Mixture of Flag-TDP-43- and TDP-43-expressing HEK 293T cell lysates. The phosphorylated
TDP-43 was detected only in the late stage (asterisk).
Figure 7 Effect of TDP-43-expressing AAV in rat spinal cords. (A) Ratio of exogenously expressed Flag-TDP-43 messenger RNA level to
endogenous rat or cynomolgus TDP-43 messenger RNA level evaluated by quantitative real-time polymerase chain reaction.
Mean   SEM, rat, n = 4; cynomolgus, n =3 ,P = 0.74. (B) Time course of grip strength. Mean   SEM. (C) Nuclear staining of exogenous
TDP-43 in cervical cord sections of AAV-injected rats by immunostaining with an anti-Flag antibody (arrows). (D) Immunostaining of
cervical cord sections of TDP-43–expressing rat, 4 weeks after injection, with SMI31 did not show aberrant phosphorylated neuroﬁlament
in the neuronal cytoplasm. Scale bars: 20mm.
844 | Brain 2012: 135; 833–846 A. Uchida et al.necessary to initiate motor symptoms and is a late event in moto-
neuron degeneration.
In the spinal cords of our monkeys, neither a C-terminal nor a
phosphospeciﬁc TDP-43 antibody detected the 25-kDa C-terminal
fragment that is found in patients with ALS. Overexpressed
25-kDa C-terminal fragment in cultured cells is reported to be
toxic (Igaz et al., 2009; Zhang et al., 2009), and the accumulation
of 25-kDa C-terminal fragment in transgenic mouse brain correl-
ates with disease progression (Xu et al., 2010). Interestingly,
unlike the FTLD/ALS brain, the 25-kDa C-terminal fragment is
often absent in the ALS spinal cord (Neumann et al., 2009). The
absence of 25-kDa C-terminal fragment in ALS spinal cord does
not necessarily preclude a primary role for this form; rather it can
be pathologically crucial if its absence is due to the accelerated
degeneration of motoneurons with 25-kDa C-terminal fragment. It
is difﬁcult to deny that small amounts of C-terminal truncated
species are actually present, because mislocalization of TDP-43
was focal in the spinal cord of our monkeys. However, the failure
to detect 25-kDa C-terminal fragment in our monkey spinal cord
at the early stage may have an implication that full-length TDP-43
is sufﬁcient to be toxic, because -motor axonal excitability was
impaired but their cell bodies were preserved at autopsy.
The results of studies on the relationship between TDP-43 mis-
localization and neuron loss remain controversial. The overexpres-
sion of wild-type TDP-43 in the nuclei in a transgenic rodent
model was sufﬁcient to be toxic to spinal motoneurons
(Li et al., 2010; Shan et al., 2010; Wils et al., 2010; Xu et al.,
2010), which is consistent with our observations in the rat model.
In this context, it can be interpreted that the cytoplasmic mislo-
calization of wild-type TDP-43 is an epiphenomenon and not a
necessary condition for the disease. However, in our monkey
model, TDP-43 mislocalization was detected in almost all of the
large motoneurons of the lateral nuclear group at the early or
even the presymptomatic stage, and these motoneurons later
showed neuron loss. In contrast, overexpressed exogenous
TDP-43 in the large motoneurons of the ventromedial nuclear
group was restricted to the nucleus, but did not produce neuron
loss. Mice with over-expression of human TDP-43 engineered to
localize in the cytoplasm showed progressive neuronal loss and
downregulation of endogenous nuclear mouse TDP-43 expression
(Igaz et al., 2011). These suggest that TDP-43 mislocalization is an
upstream event in the cascade of motoneuronal degeneration.
This ﬁnding is consistent with the observation that the highest
percentage of neurons with TDP-43 mislocalization was found in
the early stage of ALS in patients (Giordana et al., 2010).
In conclusion, our monkey model is superior to rodent models in
recapitulating the TDP-43 pathology and in the presence of
Bunina body-like inclusion and is expected to be a powerful tool
for investigating developing effective therapies as well as the dis-
ease pathogenesis of sporadic ALS.
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